Patrick Hwu: Exploring the unique partnership between Moffitt Cancer Center and Iovance Biotherapeutics
Patrick Hwu, President and CEO of Moffitt Cancer Center, shared a post on LinkedIn:
“Join us for a Webinar exploring the unique partnership between Moffitt Cancer Center and Iovance Biotherapeutics, Inc., to bring new cell therapies to market. The speakers will discuss key elements of how the organizations worked together to obtain approval for Iovance’s AMTAGVI, a new cell therapy for melanoma.
Learn more about the expanding capabilities of Moffitt’s Cell Therapies and Gene Engineering Facility.
Bring your questions and bring your colleagues!”
More posts featuring Patrick Hwu.
Dr. Patrick Hwu, MD, currently serves as the President and CEO of Moffitt Cancer Center. With a focus on understanding the dynamics between tumors and the immune system, Dr. Hwu’s research has been pivotal in advancing gene-modified T cell therapy.
He notably contributed seminal work on the development of the first chimeric antigen receptor aimed at combating cancer. His research portfolio extends to vaccines, adoptive T-cell therapies, and mechanisms of immune resistance.
Before joining, Dr. Hwu held numerous leadership roles at The University of Texas MD Anderson Cancer Center for over 17 years. Notably, he served as the inaugural Chairman of the Department of Melanoma Medical Oncology in 2003, as well as the Associate Director of the Center for Cancer Immunology Research. Additionally, he chaired the Department of Sarcoma Medical Oncology, demonstrating his commitment to advancing cancer treatment and research.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023